Arbutus to present at h.c. wainwright 4th annual hepatitis b virus (hbv) virtual conference

Warminster, pa., oct. 18, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the arbutus management team will participate in and host one-on-one meetings at the following investor conference:
ABUS Ratings Summary
ABUS Quant Ranking